Opioid Use Disorder App Marks A Path For 510(k) 'Breakthrough' Devices

Pear Therapeutics announced US Expedited Access Pathway designation earlier this month for its 510(k)-route reSET-O Prescription Digital Therapeutic for OUD, perhaps providing some insight into the types of products seeking a "substantial equivalence" claim that might, nonetheless, be considered breakthroughs.

A heavily studied mobile medical app intended to support treatment of opioid use disorder (OUD) is among the first 510(k)-route products to gain entry into US FDA's Breakthrough Devices Program, providing some insight into the types of products that might be considered breakthroughs even though they are seeking a "substantial equivalence" claim to something already on the market.

Pear Therapeutics announced Expedited Access Pathway designation earlier this month for its reSET-O Prescription Digital Therapeutic for OUD. FDA has recently started to refer to the 2015-launch EAP program as the Breakthrough Devices Program to align with a provision of the 21st Century Cures Act that updates the program. The agency issued a draft guidance Oct. 24 on the updated program, which offers an expedited development route for devices that may address an unmet need for life-threatening or irreversibly debilitating diseases or conditions

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Digital Technologies

Subsense Develops Nonsurgical, Nanoparticle-Based Brain-Computer Interface For Neurological Disorders

 
• By 

Neurotechnology start-up Subsense came out of stealth with $17m in seed funding to develop a nonsurgical, nanoparticle-based brain-computer interface. Medtech Insight spoke with the firm’s new neurotech lead Cyril Eleftheriou about the technology and its potentially wide applications for treating Parkinson’s, epilepsy, inner speech decoding, and more.

AAOS 2025 Orthopedic Roundup: J&J Velys UKA, Stryker Mako 4, Materialise, Canary Medical

 
• By 

At AAOS, orthopedics players showcased their latest robotic-assisted platforms, power tools, 3D printed technologies and software offerings. This article brings you highlights from interviews Medtech Insight conducted on site with representatives from J&J, Stryker, Materialise and Canary Medical.

South Korea Adds Digital Health Rules To Already Complicated Regulatory Landscape

 
• By 

A New South Korean law, the Digital Medical Products Act, enhances regulation for digital health products. Medical devices in the country are categorized both by risk and by similarity to already authorized devices. The approval process may stretch to 515 days for new manufacturers.

Abbott Embeds Libre Glucose Data In Epic EHR, Expanding Digital Health Footprint

 
• By 

Through this partnership, data stored in LibreView – Abbott’s cloud-based diabetes data management system – can automatically flow into Epic, allowing clinicians using Epic to view a patient’s CGM data before, during and after visits without toggling between systems or requesting manual uploads.

More from Medtech Insight

Don’t Sleep On Inspections: Experts Warn FDA Maintains Enforcement Resources

 

Manufacturers of medical products would be foolish to think that recent upheavals at the US FDA will result in a lack of inspections in the coming years. A panel of experts discussed the current state of inspections during a webinar hosted by the Food and Drug Law Institute.

Global Medtech Guidance Tracker: April 2025

 
• By 

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. 25 documents have been posted on the tracker since its last update.

Execs On The Move: 14-18 April 2025

 
• By 

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.